Strides Pharma Science Limited (NSE:STAR)
India
· Delayed Price · Currency is INR 608.40
-18.40 (-2.94%)
Mar 12, 2025, 3:30 PM IST
Strides Pharma Science Revenue
Strides Pharma Science had revenue of 11.54B INR in the quarter ending December 31, 2024, with 11.18% growth. This brings the company's revenue in the last twelve months to 45.79B, up 15.83% year-over-year. In the fiscal year ending March 31, 2024, Strides Pharma Science had annual revenue of 40.51B with 9.83% growth.
Revenue (ttm)
45.79B
Revenue Growth
+15.83%
P/S Ratio
1.26
Revenue / Employee
14.94M
Employees
3,065
Market Cap
57.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 40.51B | 3.63B | 9.83% |
| Mar 31, 2023 | 36.88B | 6.18B | 20.13% |
| Mar 31, 2022 | 30.70B | -2.46B | -7.41% |
| Mar 31, 2021 | 33.16B | 5.64B | 20.49% |
| Mar 31, 2020 | 27.52B | 5.74B | 26.33% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Zydus Lifesciences | 222.47B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Strides Pharma Science News
- 5 weeks ago - Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25 - Business Upturn
- 5 weeks ago - Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY - Business Upturn
- 7 weeks ago - Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio - Business Upturn
- 4 months ago - Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high - Business Upturn
- 5 months ago - OneSource raises Rs 801 crore from investors, boosts growth for Strides shareholders - Business Upturn
- 6 months ago - Strides Pharma shares surge 3% on USFDA nod for Fluoxetine Tabs 60 mg - Business Upturn
- 6 months ago - Strides Pharma gets USFDA approval for Fluoxetine Tabs 60 mg - Business Upturn
- 6 months ago - Strides Pharma secures approval for OneSource, India’s first specialty pharma CDMO - Business Upturn